Tumor suppressor U19/EAF2 regulates thrombospondin-1 expression via p53

Oncogene

Volumn 29, Issue 3, 2010, Pages 421-431

  Su, F ^a   Pascal, L E ^a   Xiao, W ^b   Wang, Z ^a,c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b INSTITUTE OF HYDROBIOLOGY   (China)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

P53; Prostate cancer; TSP 1; Tumor suppressor; U19 EAF2

Indexed keywords

CD31 ANTIGEN; LUCIFERASE; PROTEIN P53; THROMBOSPONDIN 1;

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; ELL ASSOCIATED FACTOR 2 GENE; GENE CONTROL; GENE EXPRESSION; GENE REPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LIVER; LIVER BLOOD VESSEL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE; PROTEIN LOCALIZATION; REPORTER GENE; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTIGENS, CD31; BLOOD VESSELS; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LIVER; LUMINESCENT PROTEINS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSCOPY, FLUORESCENCE; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; PROSTATE; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THROMBOSPONDIN 1; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 75149141252     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.326     Document Type: Article

References (28)

1. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. (1990). Basic local alignment search tool. J Mol Biol 215: 403-410.
2. Alvarez AA, Axelrod JR, Whitaker RS, Isner PD, Bentley RC, Dodge RK et al. (2001). Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients. Gynecol Oncol 82: 273-278.
3. Azam N, Vairapandi M, Zhang W, Hoffman B, Liebermann DA. (2001). Interaction of CR6 (GADD45gamma) with proliferating cell nuclear antigen impedes negative growth control. J Biol Chem 276: 2766-2774.
4. Cinatl Jr J, Kotchetkov R, Scholz M, Cinatl J, Vogel JU, Driever PH et al. (1999). Human cytomegalovirus infection decreases expression of thrombospondin-1 independent of the tumor suppressor protein p53. Am J Pathol 155: 285-292.
5. Donoviel DB, Framson P, Eldridge CF, Cooke M, Kobayashi S, Bornstein P. (1988). Structural analysis and expression of the human thrombospondin gene promoter. J Biol Chem 263: 18590-18593.
6. Duan X, Zhang H, Liu B, Li XD, Gao QX, Wu ZH. (2008). Apoptosis of murine melanoma cells induced by heavy-ion radiation combined with Tp53 gene transfer. Int J Radiat Biol 84: 211-217.
7. Framson P, Bornstein P. (1993). A serum response element and a binding site for NF-Y mediate the serum response of the human thrombospondin 1 gene. J Biol Chem 268: 4989-4996.
8. Freitas TM, Miguel MC, Silveira EJ, Freitas RA, Galvao HC. (2005). Assessment of angiogenic markers in oral hemangiomas and pyogenic granulomas. Exp Mol Pathol 79: 79-85.
9. Harada H, Nakagawa K, Saito M, Kohno S, Nagato S, Furukawa K et al. (2003). Introduction of wild-type p53 enhances thrombos-pondin-1 expression in human glioma cells. Cancer Lett 191: 109-119.
10. Jiang C, Hu H, Malewicz B, Wang Z, Lu J. (2004). Selenite-induced p53 Ser-15 phosphorylation and caspase-mediated apoptosis in LNCaP human prostate cancer cells. Mol Cancer Ther 3: 877-884.
11. Kwak C, Jin RJ, Lee C, Park MS, Lee SE. (2002). Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia. BJU Int 89: 303-309.
12. Maeda K, Chung YS, Takatsuka S, Ogawa Y, Onoda N, Sawada T et al. (1995). Tumour angiogenesis and tumour cell proliferation as prognostic indicators in gastric carcinoma. Br J Cancer 72: 319-323.
13. Mitani K, Yamagata T, Iida C, Oda H, Maki K, Ichikawa M et al. (2000). Nonredundant roles of the elongation factor MEN in postimplantation development. Biochem Biophys Res Commun 279: 563-567.
14. Nelius T, Filleur S, Yemelyanov A, Budunova I, Shroff E, Mirochnik Y et al. (2007). Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo. Int J Cancer 121: 999-1008.
15. Reiher FK, Ivanovich M, Huang H, Smith ND, Bouck NP, Campbell SC. (2001). The role of hypoxia and p53 in the regulation of angiogenesis in bladder cancer. J Urol 165: 2075-2081.
16. Ren B, Yee KO, Lawler J, Khosravi-Far R. (2006). Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta 1765: 178-188.
17. Roe JS, Kim H, Lee SM, Kim ST, Cho EJ, Youn HD. (2006). p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell 22: 395-405.
18. Selfridge J, Pow AM, McWhir J, Magin TM, Melton DW. (1992). Gene targeting using a mouse HPRT minigene/HPRT-deficient embryonic stem cell system: inactivation of the mouse ERCC-1 gene. Somat Cell Mol Genet 18: 325-336.
19. Shinobu N, Maeda T, Aso T, Ito T, Kondo T, Koike K et al. (1999). Physical interaction and functional antagonism between the RNA poly-merase II elongation factor ELL and p53. J Biol Chem 274: 17003-17010.
20. Simone F, Luo RT, Polak PE, Kaberlein JJ, Thirman MJ. (2003). ELL-associated factor 2 (EAF2), a functional homolog of EAF1 with alternative ELL binding properties. Blood 101: 2355-2362.
21. Tokunaga T, Nakamura M, Oshika Y, Tsuchida T, Kazuno M, Fukushima Y et al. (1998). Alterations in tumour suppressor gene p53 correlate with inhibition of thrombospondin-1 gene expression in colon cancer cells. Virchows Arch 433: 415-418.
22. Wang Z, Tufts R, Haleem R, Cai X. (1997). Genes regulated by androgen in the rat ventral prostate. Proc Natl Acad Sci USA 94: 12999-13004.
23. Wiederschain D, Kawai H, Gu J, Shilatifard A, Yuan ZM. (2003). Molecular basis of p53 functional inactivation by the leukemic protein MLL-ELL. Mol Cell Biol 23: 4230-4246.
24. Xiao W, Jiang F, Wang Z. (2006). ELL binding regulates U19/Eaf2 intracellular localization, stability, and transactivation. Prostate 66: 1-12.
25. Xiao W, Zhang Q, Habermacher G, Yang X, Zhang AY, Cai X et al. (2008). U19/Eaf2 knockout causes lung adenocarcinoma, B-cell lymphoma, hepatocellular carcinoma and prostatic intraepithelial neoplasia. Oncogene 27: 1536-1544.
26. Xiao W, Zhang Q, Jiang F, Pins M, Kozlowski JM, Wang Z. (2003). Suppression of prostate tumor growth by U19, a novel testosterone-regulated apoptosis inducer. Cancer Res 63: 4698-4704.
27. Xiao W, Ai J, Habermacher G, Volpert O, Yang X, Zhang AY et al. (2009). U19/Eaf2 binds to and stabilizes von hippel-lindau protein. Cancer Res 69: 2599-2606.
28. Zhou J, Feng X, Ban B, Liu J, Wang Z, Xiao W. (2009). Elongation factor ELL (Eleven-Nineteen Lysine-rich Leukemia) acts as a transcription factor for direct thrombospondin-1 regulation. J Biol Chem 284: 19142-19152.